6:33 PM
 | 
Sep 01, 2009
 |  BC Extra  |  Clinical News

Gene Signal reports GS-101 data

Gene Signal S.A.S. (Lausanne, Switzerland) said interim data showed 86 ug/day of topical GS-101 met the primary endpoint vs. placebo in a Phase II...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >